Kromek’s Digital Detectors Used in World’s 1st Digital SPECT/CT Scanner for Higher Energy Imaging

Detectors provide Spectrum Dynamics Medical’s digital SPECT/CT scanner with higher sensitivity and throughput

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that one of its key customers, Spectrum Dynamics Medical, has introduced the world’s first digital SPECT/CT scanner for higher energy imaging, using Kromek’s digital detectors.

Based on Spectrum Dynamics’ digital SPECT/CT platform, VERITON-CT 400 Series’ detector technology provides the benefits of increased sensitivity and throughput for Nuclear Medicine clinical applications using up to 400keV high-energy isotopes.

CZT is transforming the detector technology used in medical imaging leading to shorter scan times, lower radiation dose to the patient, and improved image quality and quantitative accuracy.

Kromek’s high-performance digital detectors, combined with Spectrum’s 360-degree, wide-bore SPECT/CT scanner and its advanced image reconstruction algorithms, increase the energy range up to 400 keV to support the throughput demand of current and new emerging nuclear medicine clinical applications.

The 400 Series digital detector technology sets new standards with a 2-4 times improvement in energy range, system sensitivity, and energy resolution. These improvements will significantly shorten the scan times associated with current analog or state-of-the-art digital technology.

Arnab Basu, CEO of Kromek Group, said: “We are delighted that our CZT detectors have been integrated into Spectrum Dynamics’ VERITON-CT 400 SPECT/CT systems. This enables enhanced image quality and breakthrough clinical capabilities in digital SPECT/CT. Spectrum Dynamics has long been at the forefront of developing next-generation SPECT/CT scanners to deliver better patient outcomes, and we are pleased to be part of this significant advance in nuclear medical imaging technology.”

Gilad Yoeli, CEO of Spectrum Dynamics, added: “Clinical users across the world provide us with feedback on the Nuclear Medicine challenges they face. Providing the technology to address such challenges is what drives us. The increased sensitivity, improved energy resolution, and broader energy range of Kromek’s detector technology make it the right choice for the 400 Series and the advanced imaging and quantitative accuracy clinical users ask for.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.